Is cytomegalovirus viraemia a useful tool in managing CMV disease?

Sexually Transmitted Infections

Volumn 76, Issue 5, 2000, Pages 342-344

  Deayton, J R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ALGORITHM; ARTICLE; CLINICAL PROTOCOL; CYTOMEGALOVIRUS INFECTION; HIGH RISK PATIENT; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; VIREMIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALGORITHMS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS RETINITIS; DRUG RESISTANCE, MICROBIAL; HUMANS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; VIREMIA;

EID: 0033768828     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.76.5.342     Document Type: Article

References (32)

1. Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections
2. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation
3. Interrelationships between quantity of cytomegalovirus DNA in blood, donor/recipient status and augmented prednisolone as risk factors for HCMV disease following liver transplantation
4. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant recipients: Relationship between peak virus load, donor/recipient serostatus, GvHD and CMV disease
5. Cytomegalovirus viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease
6. Utility of urine and leukocyte culture and plasma DNA for identification of HIV patients at risk for human CMV disease
7. Development of CMV disease may be predicted in HIV-infected patients by CMV PCR and the antigenaemia test
8. Plasma CMV DNA load predicts CMV disease and survival in AIDS patients
9. Quantitative effects of valaciclovir on the replication of cytomegalovirus in persons with advanced human immunodeficiency virus disease: Baseline CMV load dictates time to disease and survival JID
10. Cytomegalovirus DNA load is an independent predictor of CMV disease and survival in advanced AIDS
11. Natural history of untreated cytomegalovirus retinitis
12. Cytomegalovirus retinitis in AIDS patients: Influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival
13. Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis
14. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
15. A randomized, double-blind trial of valaciclovir prophylaxis for CMV disease in patients with advanced human immunodeficiency virus infection
16. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
17. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors
18. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
19. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis
20. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS
21. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome
22. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis
23. Loss of cytomegalovirus viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy
24. Incidence and risk factors for developing cytomegalovirus retrains in HIV-infected patients receiving protease inhibitor therapy
25. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
26. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts
27. Lack of reactivation of cytomegalovirus retinitis after stopping CMV maintenance therapy in patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
28. Discontinuing anticytomegalovirus therapy in patients with immune restoration after combination antiretroviral therapy
29. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
30. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy
31. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease m patients receiving highly active antiretroviral therapy